Proteomic comparison between different tissue preservation methods for identification of promising biomarkers of urothelial bladder cancer

被引:10
|
作者
Valdes, Alberto [1 ,2 ]
Bitzios, Athanasios [1 ]
Kassa, Eszter [1 ]
Shevchenko, Ganna [1 ]
Falk, Alexander [1 ]
Malmstrom, Per-Uno [3 ]
Dragomir, Anca [4 ,5 ]
Segersten, Ulrika [3 ]
Lind, Sara Bergstrom [1 ]
机构
[1] Uppsala Univ, Dept Chem BMC, Analyt Chem, Box 599, S-75124 Uppsala, Sweden
[2] CSIC, Lab Food, Inst Food Sci Res, CIAL, Nicolas Cabrera 9, Madrid 28049, Spain
[3] Uppsala Univ, Akad Hosp, Dept Surg Sci, Urol, S-75185 Uppsala, Sweden
[4] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[5] Uppsala Univ Hosp, Dept Pathol, S-75185 Uppsala, Sweden
基金
瑞典研究理事会; 奥地利科学基金会;
关键词
MASS-SPECTROMETRY; THERAPEUTIC TARGET; CARCINOMA; EXPRESSION; PATHWAYS; CELLS; TUFM;
D O I
10.1038/s41598-021-87003-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Samples in biobanks are generally preserved by formalin-fixation and paraffin-embedding (FFPE) and/or optimal cutting temperature compound (OCT)-embedding and subsequently frozen. Mass spectrometry (MS)-based analysis of these samples is now available via developed protocols, however, the differences in results with respect to preservation methods needs further investigation. Here we use bladder urothelial carcinoma tissue of two different tumor stages (Ta/T1-non-muscle invasive bladder cancer (NMIBC), and T2/T3-muscle invasive bladder cancer (MIBC)) which, upon sampling, were divided and preserved by FFPE and OCT. Samples were parallel processed from the two methods and proteins were analyzed with label-free quantitative MS. Over 700 and 1200 proteins were quantified in FFPE and OCT samples, respectively. Multivariate analysis indicates that the preservation method is the main source of variation, but also tumors of different stages could be differentiated. Proteins involved in mitochondrial function were overrepresented in OCT data but missing in the FFPE data, indicating that these proteins are not well preserved by FFPE. Concordant results for proteins such as HMGCS2 (uniquely quantified in Ta/T1 tumors), and LGALS1, ANXA5 and plastin (upregulated in T2/T3 tumors) were observed in both FFPE and OCT data, which supports the use of MS technology for biobank samples and encourages the further evaluation of these proteins as biomarkers.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Scoring photographic assessment of normal tissue effects after radiotherapy for early breast cancer - a comparison of two different methods
    Sydenham, M.
    Haviland, J.
    Bliss, J.
    Gothard, L.
    Tait, D.
    Yarnold, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 207 - 207
  • [42] Molecular Subtypes in Muscle-Invasive Urothelial Bladder Cancer (MIBC): Comparison of 2 Sequencing Methods - Evaluation of Their Predictive Role in Adjuvant Chemotherapy and Impact of Tumor Microenvironment
    Koll, Florestan J.
    Doering, Claudia
    Herwig, Leon
    Olah, Csilla
    Szarvas, Tibor
    Koellermann, Jens
    Garcia, Cristina Cano
    Wenzel, Mike
    Hoeh, Benedikt
    Banek, Severine
    Kluth, Luis
    Chun, Felix K. H.
    Wild, Peter J.
    Reis, Henning
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (06): : S49 - S50
  • [43] A Comparison of Different Prophylactic Intravesical Chemotherapy Regimens for Bladder Cancer Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinomas: A Retrospective 2-center Study
    Huang, Yong
    Cen, Junjie
    Liu, Zhuowei
    Wei, Jinhuan
    Chen, Zhenhua
    Feng, Zihao
    Lu, Jun
    Fang, Yong
    Zhou, Fangjian
    Luo, Junhang
    Mo, Chengqiang
    Chen, Wei
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2019, 18 : 1 - 9
  • [44] Five-year survival comparison of different treatment modalities for muscle invasive urothelial carcinoma, squamous cell carcinoma and adenocarcinoma of the bladder: An analysis of the National Cancer Database.
    Rivera, Carlos
    Jabbal, Iktej Singh
    Yaghi, Marita
    Landau, Kevin Scott
    Muruve, Nicolas
    Saravia, Diana
    George, Tiffany L.
    Nahleh, Zeina A.
    Arteta-Bulos, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [45] miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer
    Ghorbanmehr, Nassim
    Gharbi, Sedigheh
    Korsching, Eberhard
    Tavallaei, Mahmood
    Einollahi, Behzad
    Mowla, Seyed Javad
    PROSTATE, 2019, 79 (01): : 88 - 95
  • [46] A comparison of different methods for including 'age at menopause' in analyses of the association between hormone replacement therapy use and breast cancer
    Simpson, Julie A.
    English, Dallas R.
    MacInnis, Robert J.
    Gertig, Dorota M.
    Hopper, John L.
    Giles, Graham G.
    JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2007, 33 (01): : 11 - 16
  • [47] A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancer
    Yi, Suqin
    Zhuang, Yuan
    Zhou, Jun
    Ma, Haitao
    Huang, Jianan
    Wang, Lin
    Zhu, Weidong
    Kang, Suya
    Guo, Linchuan
    Guo, Feng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 (02) : 464 - 474
  • [48] A comparison of epidermal growth factor receptor (EGFR) mutation testing methods in different tissue types in ton small cell Lung cancer
    Guo, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens
    Florestan J. Koll
    Claudia Döring
    Csilla Olah
    Tibor Szarvas
    Jens Köllermann
    Benedikt Hoeh
    Felix K.-H. Chun
    Henning Reis
    Peter J. Wild
    BMC Cancer, 23
  • [50] Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens
    Koll, Florestan J. J.
    Doering, Claudia
    Olah, Csilla
    Szarvas, Tibor
    Koellermann, Jens
    Hoeh, Benedikt
    Chun, Felix K. -H.
    Reis, Henning
    Wild, Peter J.
    BMC CANCER, 2023, 23 (01)